 Bhautesh D Jani¹, Frederick K Ho[*], David J Lowe, Jamie P Traynor, Sean MacBride-Stewart, Patrick B Mark, Frances S Mair, Jill P Pell* ¹Joint-first author Bhautesh D Jani PhD Clinical Senior Lecturer in General Practice and Primary Care Institute of Health and Wellbeing, University of Glasgow Glasgow G12 9LX, UK Bhautesh Janie glasgow.ac.uk Frederick K Ho PhD Research Associate Institute of Health and Wellbeing, University of Glasgow Glasgow, G12 8RZ, UK Prederick.Hoe glasgow.ac.uk Prederick.Hoe glasgow.ac.uk David J Lowe MSc Consultant in Emergency Medicine Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G2 4TF, UK David.Jowe@nhs.net Jamie P Traynor MD Consultant Nephrologist Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK Jamie Traynor MD Consultant Nephrologist Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK Jamie Traynor MD Lead Pharmacist (Medicines Management Resources) Pharmacy Services, NHS Greater Glasgow and Clyde Glasgow, G76 7AT, UK Sean MacBride-Stewart@gc_scot.nhs.uk Patrick B Mark PhD Professor of Nephrology Institute of Cardiovascular and Medical Sciences, University of Glasgow Glasgow, G12 AT, UK Patrick Mark @glasgow.ac.uk Frances S Mair MD Norie Miller Professor of General Practice Norie Miller Mod Wellbein University of Glasgow 	1 2	Comparison of COVID-19 outcomes among shielded and non-shielded populations: A general population cohort study of 1.3 million
5 Bhautesh D Jani [†] , Frederick K Ho [†] , David J Lowe, Jamie P Traynor, Sean MacBride-Stewart, 6 Bhautesh D Jani [†] , Frederick K Ho [†] , David J Lowe, Jamie P Traynor, Sean MacBride-Stewart, 7 Patrick B Mark, Frances S Mair, Jill P Pell* 8 [†] Joint-first author 10 Bhautesh D Jani PhD 12 Clinical Senior Lecturer in General Practice and Primary Care 13 Institute of Health and Wellbeing, University of Glasgow 14 Glasgow G12 9LX, UK 15 Bhautesh, jani@glasgow.ac.uk 16 Frederick K Ho PhD 17 Frederick K Ho PhD 18 Research Associate 19 Institute of Health and Wellbeing, University of Glasgow 20 Glasgow, G12 8RZ, UK 21 Frederick Ho@glasgow.ac.uk 22 David J Lowe MSc 23 David J Lowe MSc 24 Consultant in Emergency Medicine 25 Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde 26 Glasgow, G52 4TF, UK 29 Jamie P Traynor MD 20 Consultant Nephrologist 31 Queen Elizabeth University Hospital, NHS Greater Glasgow		
 Bhautesh D Jani[†], Frederick K Ho[†], David J Lowe, Jamie P Traynor, Sean MacBride-Stewart, Patrick B Mark, Frances S Mair, Jill P Pell[*] [†]Joint-first author Bhautesh D Jani PhD Clinical Senior Lecturer in General Practice and Primary Care Institute of Health and Wellbeing, University of Glasgow Glasgow G12 9LX, UK Bhautesh,jani@glasgow.ac.uk Frederick K Ho PhD Research Associate Institute of Health and Wellbeing, University of Glasgow Glasgow, G12 8RZ, UK David J Lowe MSc Consultant in Emergency Medicine Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK Jamie Traynor MD Consultant Nephrologist Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK Jamie Traynor MD Consultant Nephrologist Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK Jamie Traynor MD Consultant Nephrologist Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK Jamie Traynor MD Consultant Nephrologist Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK Jamie traynor@gc.scot.nhs.uk 44 45 Yean MacBride-Stewart PhD Lead Pharmacist (Medicines Management Resources) Pharmacy Services, NHS Greater Glasgow and Clyde Glasgow, G76 7AT, UK Sean MacBride-Stewart @gc.scot.nhs.uk 46 Patrick B Mark PhD Professor of Nephrology Institute of Cardiovascular and Medical Sciences, University of Glasgow Glasgow, G12 8TA, UK PatrickMark@glasgow.ac.uk Frances S Mair MD Norie Miller Professor of General Practice 		
 Patrick B Mark, Frances S Mair, Jill P Pell* [†]Joint-first author [†]Bhautesh D Jani PhD Clinical Senior Lecturer in General Practice and Primary Care Institute of Health and Wellbeing, University of Glasgow Glasgow GI 2 9LX, UK Bhautesh, jani@glasgow.ac.uk [†]Frederick K Ho PhD Research Associate Institute of Health and Wellbeing, University of Glasgow Glasgow, GI 2 8RZ, UK Prederick Ho PhD Research Associate Institute of Health and Wellbeing, University of Glasgow Glasgow, GI 2 8RZ, UK Prederick Ho@glasgow.ac.uk [†]Consultant in Emergency Medicine Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK David Lowe@nhs.net Jamie P Traynor MD Consultant Nephrologist Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK Jamie P Traynor MD Consultant Nephrologist Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK Jamie traynor@gc.scot.nhs.uk ⁴⁴ Sean MacBride-Stewart PhD Lead Pharmacist (Medicines Management Resources) Pharmacy Services, NHS Greater Glasgow and Clyde Glasgow, G76 7AT, UK Sean.MacBride-Stewart@gc.scot.nhs.uk ⁴⁰ Patrick B Mark PhD Professor of Nephrology Institute of Cardiovascular and Medical Sciences, University of Glasgow Glasgow, G12 RA, UK Patrick.Mark@glasgow.ac.uk ⁴¹ ⁴² Patrick.Mark@glasgow.ac.uk ⁴⁴ ⁴⁵ Patrick.Mark@glasgow.ac.uk ⁴⁶ ⁴⁷ Prances S Mair MD Norie Miller Professor of General Practice 		
8 *Joint-first author 9 *Joint-first author 10 Bhautesh D Jani PhD 11 Bhautesh D Jani PhD 12 Clinical Senior Lecturer in General Practice and Primary Care 13 Institute of Health and Wellbeing, University of Glasgow 14 Glasgow G12 9LX, UK 15 Bhautesh.jani@glasgow.ac.uk 16 ************************************		
 ⁹ [†]Joint-first author ¹⁰ ¹⁰ Bhautesh D Jani PhD ¹² Clinical Senior Lecturer in General Practice and Primary Care ¹³ Institute of Health and Wellbeing, University of Glasgow ¹⁴ Glasgow G12 9LX, UK ¹⁶ Bhautesh,jani@glasgow.ac.uk ¹⁷ Frederick K Ho PhD ¹⁸ Research Associate ¹⁹ Institute of Health and Wellbeing, University of Glasgow ¹⁰ Glasgow, G12 8RZ, UK ¹⁷ Frederick.Ho@glasgow.ac.uk ¹⁸ Prederick.Ho@glasgow.ac.uk ¹⁹ Institute of Health and Wellbeing, University of Glasgow ¹⁰ Glasgow, G12 8RZ, UK ¹⁰ Frederick.Ho@glasgow.ac.uk ²¹ Oavid J Lowe MSc ²² Consultant in Emergency Medicine ²⁰ Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde ²¹ Glasgow, G52 4TF, UK ²³ David.lowe@nhs.net ²⁴ ²⁵ Sean MacBride-Stewart PhD ²⁶ Lead Pharmacist (Medicines Management Resources) ²⁶ Pharmacy Services, NHS Greater Glasgow and Clyde ²⁷ Glasgow, G7 67 AT, UK ²⁸ Sean MacBride-Stewart PhD ²⁹ Lead Pharmacist (Medicines Management Resources) ²¹ Pharmacy Services, NHS Greater Glasgow and Clyde ²⁴ Glasgow, G7 67 AT, UK ²⁵ Sean MacBride-Stewart @gc.scot.nhs.uk ⁴⁰ ⁴¹ Patrick B Mark PhD ⁴² Professor of Nephrology ⁴³ Institute of Cardiovascular and Medical Sciences, University of Glasgow ⁴⁴ Glasgow, G12 8TA, UK ⁴⁵ Patrick.Mark@glasgow.ac.uk ⁴⁶ ⁴⁷ Frances S Mair MD ⁴⁸ Norie Miller Professor of General Practice 		Patrick B Mark, Frances S Mair, Jill P Pell*
10 Bhautesh D Jani PhD 11 Bhautesh D Jani PhD 12 Clinical Senior Lecturer in General Practice and Primary Care 13 Institute of Health and Wellbeing, University of Glasgow 14 Glasgow G12 9LX, UK 15 Bhautesh jani@glasgow.ac.uk 16 Frederick K Ho PhD 17 Frederick K Ho PhD 18 Research Associate 19 Institute of Health and Wellbeing, University of Glasgow 10 Glasgow, G12 8RZ, UK 21 Frederick. Ho@glasgow.ac.uk 22 David J Lowe MSc 23 David J Lowe MSc 24 Consultant in Emergency Medicine 25 Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde 26 Glasgow, G52 4TF, UK 27 David.lowe@nhs.net 28 Jamie P Traynor MD 30 Consultant Nephrologist 31 Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde 33 Jamie.traynor@ggc.scot.nhs.uk 34 Jamie.traynor@ggc.scot.nhs.uk 35 Sean MacBride-Stewart PhD 36 Lead Phar		[†] Loint first author
11 Bhautesh D Jani PhD 12 Clinical Senior Lecturer in General Practice and Primary Care 13 Institute of Health and Wellbeing, University of Glasgow 14 Glasgow G12 9LX, UK 15 Bhautesh,jani@glasgow.ac.uk 16		Joint-mist aution
12 Clinical Senior Lecturer in General Practice and Primary Care 13 Institute of Health and Wellbeing, University of Glasgow 14 Glasgow G12 9LX, UK 15 Bhautesh.jani@glasgow.ac.uk 16 Frederick K Ho PhD 17 Frederick K Ho PhD 18 Research Associate 19 Institute of Health and Wellbeing, University of Glasgow 20 Glasgow, G12 8RZ, UK 21 Frederick.Ho@glasgow.ac.uk 22 David J Lowe MSc 23 David J Lowe MSc 24 Consultant in Emergency Medicine 25 Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde 26 Glasgow, G52 4TF, UK 27 David.lowe@nhs.net 28		Bhautesh D Jani PhD
 Institute of Health and Wellbeing, University of Glasgow Glasgow G12 9LX, UK Bhautesh, jani@glasgow.ac.uk Frederick K Ho PhD Research Associate Institute of Health and Wellbeing, University of Glasgow Glasgow, G12 8RZ, UK Frederick.Ho@glasgow.ac.uk Grasgow, G12 8RZ, UK Frederick.Ho@glasgow.ac.uk Oavid J Lowe MSc Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK David.lowe@nhs.net Jamie P Traynor MD Consultant Nephrologist Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK Jamie P Traynor MD Consultant Nephrologist Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK Jamie P Traynor MD Consultant Nephrologist Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK Jamie.traynor@gc.scot.nhs.uk Fead Pharmacist (Medicines Management Resources) Pharmacy Services, NHS Greater Glasgow and Clyde Glasgow, G76 7AT, UK Sean MacBride-Stewart PhD Lead Pharmacist (Medicines Management Resources) Pharmacy Services, NHS Greater Glasgow and Clyde Glasgow, G76 7AT, UK Sean.MacBride-Stewart@gc.scot.nhs.uk Professor of Nephrology Institute of Cardiovascular and Medical Sciences, University of Glasgow Glasgow, G12 8TA, UK Patrick.Mark@glasgow.ac.uk Frances S Mair MD Norie Miller Professor of General Practice 		
14 Glasgow G12 9LX, UK 15 Bhautesh.jani@glasgow.ac.uk 16		•
15 Bhautesh.jani@glasgow.ac.uk 16 17 Frederick K Ho PhD 18 Research Associate 19 Institute of Health and Wellbeing, University of Glasgow 20 Glasgow, G12 8RZ, UK 21 Frederick.Ho@glasgow.ac.uk 22 David J Lowe MSc 23 David J Lowe MSc 24 Consultant in Emergency Medicine 25 Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde 26 Glasgow, G52 4TF, UK 27 David.lowe@nhs.net 28 Jamie P Traynor MD 30 Consultant Nephrologist 31 Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde 32 Glasgow, G52 4TF, UK 33 Jamie Lraynor@gcc.scot.nhs.uk 34 Jamie.traynor@gcg.scot.nhs.uk 35 Sean MacBride-Stewart PhD 36 Lead Pharmacist (Medicines Management Resources) 37 Pharmacy Services, NHS Greater Glasgow and Clyde 38 Glasgow, G76 7AT, UK 39 Sean MacBride-Stewart@gcs.scot.nhs.uk 40 Patrick B Mark PhD		τ · · ·
16 Frederick K Ho PhD 18 Research Associate 19 Institute of Health and Wellbeing, University of Glasgow 20 Glasgow, G12 8RZ, UK 11 Frederick.Ho@glasgow.ac.uk 22 David J Lowe MSc 23 David J Lowe MSc 24 Consultant in Emergency Medicine 25 Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde 26 Glasgow, G52 4TF, UK 29 Jamie P Traynor MD 30 Consultant Nephrologist 31 Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde 31 Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde 33 Jamie Traynor MD 34 Glasgow, G52 4TF, UK 34 Jamie.traynor@gcc.scot.nhs.uk 34 Glasgow, G52 4TF, UK 34 Jamie.traynor@gcc.scot.nhs.uk 35 Sean MacBride-Stewart PhD 36 Lead Pharmacist (Medicines Management Resources) 37 Pharmacy Services, NHS Greater Glasgow and Clyde 38 Glasgow, G76 7A T, UK 39 Sean.MacBride-Stewart@gcc.scot.nhs.uk		
 18 Research Associate 19 Institute of Health and Wellbeing, University of Glasgow 19 Glasgow, G12 8RZ, UK 20 Frederick.Ho@glasgow.ac.uk 21 Prederick.Ho@glasgow.ac.uk 22 23 David J Lowe MSc 24 Consultant in Emergency Medicine 25 Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde 26 Glasgow, G52 4TF, UK 27 David.lowe@nhs.net 28 29 Jamie P Traynor MD 20 Consultant Nephrologist 31 Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde 32 Glasgow, G52 4TF, UK 33 Jamie.traynor@gc.scot.nhs.uk 34 35 Sean MacBride-Stewart PhD 36 Lead Pharmacist (Medicines Management Resources) 37 Pharmacy Services, NHS Greater Glasgow and Clyde 38 Glasgow, G76 7AT, UK 39 Sean.MacBride-Stewart@gc.scot.nhs.uk 40 41 Patrick B Mark PhD 42 Professor of Nephrology 43 Institute of Cardiovascular and Medical Sciences, University of Glasgow 44 Glasgow, G12 8TA, UK 45 Patrick.Mark@glasgow.ac.uk 46 47 Frances S Mair MD 48 Norie Miller Professor of General Practice 	16	
 Institute of Health and Wellbeing, University of Glasgow Glasgow, G12 8RZ, UK Frederick.Ho@glasgow.ac.uk David J Lowe MSc Consultant in Emergency Medicine Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK David.lowe@nhs.net Consultant Nephrologist Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK Jamie P Traynor MD Consultant Nephrologist Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK Sean MacBride-Stewart PhD Lead Pharmacis (Medicines Management Resources) Pharmacy Services, NHS Greater Glasgow and Clyde Glasgow, G76 7AT, UK Sean.MacBride-Stewart @gc.scot.nhs.uk Patrick B Mark PhD Professor of Nephrology Institute of Cardiovascular and Medical Sciences, University of Glasgow Glasgow, G12 8TA, UK Patrick.Mark@glasgow.ac.uk Frances S Mair MD Norie Miller Professor of General Practice 	17	Frederick K Ho PhD
 Glasgow, G12 8RZ, UK Frederick. Ho@glasgow.ac.uk Prederick. Ho@glasgow.ac.uk David J Lowe MSc Consultant in Emergency Medicine Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK David.lowe@nhs.net Jamie P Traynor MD Consultant Nephrologist Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK David.lowe@nhs.net Jamie P Traynor MD Consultant Nephrologist Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK Jamie.traynor@gc.scot.nhs.uk Sean MacBride-Stewart PhD Lead Pharmacist (Medicines Management Resources) Pharmacy Services, NHS Greater Glasgow and Clyde Glasgow, G76 7AT, UK Sean.MacBride-Stewart@gc.scot.nhs.uk Professor of Nephrology Institute of Cardiovascular and Medical Sciences, University of Glasgow Glasgow, G12 8TA, UK Patrick.Mark@glasgow.ac.uk Frances S Mair MD Norie Miller Professor of General Practice 	18	Research Associate
21Frederick.Ho@glasgow.ac.uk222324252627282929202021222223242526272829292020212223242526272829292020212223242525262728292920202021222323242525262728292920202021222324252526272829292020202122232424252526272829292020202122232424 <tr< td=""><td>19</td><td>Institute of Health and Wellbeing, University of Glasgow</td></tr<>	19	Institute of Health and Wellbeing, University of Glasgow
 David J Lowe MSc Consultant in Emergency Medicine Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK David.lowe@nhs.net Jamie P Traynor MD Consultant Nephrologist Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK Jamie.traynor@gc.scot.nhs.uk Sean MacBride-Stewart PhD Lead Pharmacist (Medicines Management Resources) Pharmacy Services, NHS Greater Glasgow and Clyde Glasgow, G76 7AT, UK Sean.MacBride-Stewart@gc.scot.nhs.uk Patrick B Mark PhD Professor of Nephrology Institute of Cardiovascular and Medical Sciences, University of Glasgow Glasgow, G12 8TA, UK Patrick.Mark@glasgow.ac.uk Frances S Mair MD Norie Miller Professor of General Practice 		
 David J Lowe MSc Consultant in Emergency Medicine Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK David.lowe@nhs.net Jamie P Traynor MD Consultant Nephrologist Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK Jamie.traynor@ggc.scot.nhs.uk Sean MacBride-Stewart PhD Lead Pharmacist (Medicines Management Resources) Pharmacy Services, NHS Greater Glasgow and Clyde Glasgow, G76 7AT, UK Sean.MacBride-Stewart@ggc.scot.nhs.uk Patrick B Mark PhD Professor of Nephrology Institute of Cardiovascular and Medical Sciences, University of Glasgow Glasgow, G12 8TA, UK Patrick.Mark@glasgow.ac.uk Frances S Mair MD Norie Miller Professor of General Practice 		Frederick.Ho@glasgow.ac.uk
 Consultant in Emergency Medicine Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK David.lowe@nhs.net Jamie P Traynor MD Consultant Nephrologist Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK Jamie.traynor@ggc.scot.nhs.uk Sean MacBride-Stewart PhD Lead Pharmacist (Medicines Management Resources) Pharmacy Services, NHS Greater Glasgow and Clyde Glasgow, G76 7AT, UK Sean.MacBride-Stewart@ggc.scot.nhs.uk Patrick B Mark PhD Professor of Nephrology Institute of Cardiovascular and Medical Sciences, University of Glasgow Glasgow, G12 8TA, UK Patrick.Mark@glasgow.ac.uk Frances S Mair MD Norie Miller Professor of General Practice 		
 Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK David.lowe@nhs.net Jamie P Traynor MD Consultant Nephrologist Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK Jamie.traynor@ggc.scot.nhs.uk Sean MacBride-Stewart PhD Lead Pharmacist (Medicines Management Resources) Pharmacy Services, NHS Greater Glasgow and Clyde Glasgow, G76 7AT, UK Sean.MacBride-Stewart@ggc.scot.nhs.uk Patrick B Mark PhD Patrick B Mark PhD Patrick B Mark PhD Glasgow, G12 8TA, UK Patrick.Mark@glasgow.ac.uk Frances S Mair MD Norie Miller Professor of General Practice 		
 Glasgow, G52 4TF, UK David.lowe@nhs.net Jamie P Traynor MD Consultant Nephrologist Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK Jamie.traynor@gc.scot.nhs.uk Sean MacBride-Stewart PhD Lead Pharmacist (Medicines Management Resources) Pharmacy Services, NHS Greater Glasgow and Clyde Glasgow, G76 7AT, UK Sean.MacBride-Stewart@gc.scot.nhs.uk Patrick B Mark PhD Patrick B Mark PhD Patrick B Mark PhD Patrick. B Mark PhD Frances S Mair MD Norie Miller Professor of General Practice 		. .
 David.lowe@nhs.net David.lowe@nhs.net Jamie P Traynor MD Consultant Nephrologist Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK Jamie.traynor@ggc.scot.nhs.uk Sean MacBride-Stewart PhD Lead Pharmacist (Medicines Management Resources) Pharmacy Services, NHS Greater Glasgow and Clyde Glasgow, G76 7AT, UK Sean.MacBride-Stewart@ggc.scot.nhs.uk Patrick B Mark PhD Patrick B Mark PhD Institute of Cardiovascular and Medical Sciences, University of Glasgow Glasgow, G12 8TA, UK Patrick.Mark@glasgow.ac.uk Frances S Mair MD Norie Miller Professor of General Practice 		
 Jamie P Traynor MD Consultant Nephrologist Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK Jamie.traynor@ggc.scot.nhs.uk Sean MacBride-Stewart PhD Lead Pharmacist (Medicines Management Resources) Pharmacy Services, NHS Greater Glasgow and Clyde Glasgow, G76 7AT, UK Sean.MacBride-Stewart@ggc.scot.nhs.uk Yenrick B Mark PhD Patrick B Mark PhD Professor of Nephrology Institute of Cardiovascular and Medical Sciences, University of Glasgow Glasgow, G12 8TA, UK Patrick.Mark@glasgow.ac.uk Frances S Mair MD Norie Miller Professor of General Practice 		
 Jamie P Traynor MD Consultant Nephrologist Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK Jamie.traynor@ggc.scot.nhs.uk Lead Pharmacist (Medicines Management Resources) Pharmacy Services, NHS Greater Glasgow and Clyde Glasgow, G76 7AT, UK Sean.MacBride-Stewart@ggc.scot.nhs.uk Sean.MacBride-Stewart@ggc.scot.nhs.uk Glasgow, G76 7AT, UK Sean.MacBride-Stewart@ggc.scot.nhs.uk Glasgow, G76 7AT, UK Sean.MacBride-Stewart@ggc.scot.nhs.uk 40 Patrick B Mark PhD Professor of Nephrology Institute of Cardiovascular and Medical Sciences, University of Glasgow Glasgow, G12 8TA, UK Patrick.Mark@glasgow.ac.uk Frances S Mair MD Norie Miller Professor of General Practice 		David.lowe@fins.net
 Consultant Nephrologist Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Glasgow, G52 4TF, UK Jamie.traynor@ggc.scot.nhs.uk Sean MacBride-Stewart PhD Lead Pharmacist (Medicines Management Resources) Pharmacy Services, NHS Greater Glasgow and Clyde Glasgow, G76 7AT, UK Sean.MacBride-Stewart@ggc.scot.nhs.uk Yenrick B Mark PhD Patrick B Mark PhD Institute of Cardiovascular and Medical Sciences, University of Glasgow Glasgow, G12 8TA, UK Patrick.Mark@glasgow.ac.uk Frances S Mair MD Norie Miller Professor of General Practice 		Jamie P Traynor MD
 31 Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde 32 Glasgow, G52 4TF, UK 33 Jamie.traynor@ggc.scot.nhs.uk 34 35 Sean MacBride-Stewart PhD 36 Lead Pharmacist (Medicines Management Resources) 37 Pharmacy Services, NHS Greater Glasgow and Clyde 38 Glasgow, G76 7AT, UK 39 Sean.MacBride-Stewart@ggc.scot.nhs.uk 40 41 Patrick B Mark PhD 42 Professor of Nephrology 43 Institute of Cardiovascular and Medical Sciences, University of Glasgow 44 Glasgow, G12 8TA, UK 45 Patrick.Mark@glasgow.ac.uk 46 47 Frances S Mair MD 48 Norie Miller Professor of General Practice 		•
 Glasgow, G52 4TF, UK Jamie.traynor@ggc.scot.nhs.uk Sean MacBride-Stewart PhD Lead Pharmacist (Medicines Management Resources) Pharmacy Services, NHS Greater Glasgow and Clyde Glasgow, G76 7AT, UK Sean.MacBride-Stewart@ggc.scot.nhs.uk Patrick B Mark PhD Professor of Nephrology Institute of Cardiovascular and Medical Sciences, University of Glasgow Glasgow, G12 8TA, UK Patrick.Mark@glasgow.ac.uk Frances S Mair MD Norie Miller Professor of General Practice 		
 Jamie.traynor@ggc.scot.nhs.uk Sean MacBride-Stewart PhD Lead Pharmacist (Medicines Management Resources) Pharmacy Services, NHS Greater Glasgow and Clyde Glasgow, G76 7AT, UK Sean.MacBride-Stewart@ggc.scot.nhs.uk Patrick B Mark PhD Professor of Nephrology Institute of Cardiovascular and Medical Sciences, University of Glasgow Glasgow, G12 8TA, UK Patrick.Mark@glasgow.ac.uk Frances S Mair MD Norie Miller Professor of General Practice 		
 34 35 Sean MacBride-Stewart PhD 36 Lead Pharmacist (Medicines Management Resources) 37 Pharmacy Services, NHS Greater Glasgow and Clyde 38 Glasgow, G76 7AT, UK 39 Sean.MacBride-Stewart@ggc.scot.nhs.uk 40 41 Patrick B Mark PhD 42 Professor of Nephrology 43 Institute of Cardiovascular and Medical Sciences, University of Glasgow 44 Glasgow, G12 8TA, UK 45 Patrick.Mark@glasgow.ac.uk 46 47 Frances S Mair MD 48 Norie Miller Professor of General Practice 		
 36 Lead Pharmacist (Medicines Management Resources) 37 Pharmacy Services, NHS Greater Glasgow and Clyde 38 Glasgow, G76 7AT, UK 39 Sean.MacBride-Stewart@ggc.scot.nhs.uk 40 41 Patrick B Mark PhD 42 Professor of Nephrology 43 Institute of Cardiovascular and Medical Sciences, University of Glasgow 44 Glasgow, G12 8TA, UK 45 Patrick.Mark@glasgow.ac.uk 46 47 Frances S Mair MD 48 Norie Miller Professor of General Practice 		
 Pharmacy Services, NHS Greater Glasgow and Clyde Glasgow, G76 7AT, UK Sean.MacBride-Stewart@ggc.scot.nhs.uk Patrick B Mark PhD Professor of Nephrology Institute of Cardiovascular and Medical Sciences, University of Glasgow Glasgow, G12 8TA, UK Patrick.Mark@glasgow.ac.uk Frances S Mair MD Norie Miller Professor of General Practice 	35	Sean MacBride-Stewart PhD
 Glasgow, G76 7AT, UK Sean.MacBride-Stewart@ggc.scot.nhs.uk Patrick B Mark PhD Professor of Nephrology Institute of Cardiovascular and Medical Sciences, University of Glasgow Glasgow, G12 8TA, UK Patrick.Mark@glasgow.ac.uk Frances S Mair MD Norie Miller Professor of General Practice 	36	Lead Pharmacist (Medicines Management Resources)
 39 Sean.MacBride-Stewart@ggc.scot.nhs.uk 40 41 Patrick B Mark PhD 42 Professor of Nephrology 43 Institute of Cardiovascular and Medical Sciences, University of Glasgow 44 Glasgow, G12 8TA, UK 45 Patrick.Mark@glasgow.ac.uk 46 47 Frances S Mair MD 48 Norie Miller Professor of General Practice 	37	
 40 41 Patrick B Mark PhD 42 Professor of Nephrology 43 Institute of Cardiovascular and Medical Sciences, University of Glasgow 44 Glasgow, G12 8TA, UK 45 Patrick.Mark@glasgow.ac.uk 46 47 Frances S Mair MD 48 Norie Miller Professor of General Practice 	38	Glasgow, G76 7AT, UK
 41 Patrick B Mark PhD 42 Professor of Nephrology 43 Institute of Cardiovascular and Medical Sciences, University of Glasgow 44 Glasgow, G12 8TA, UK 45 Patrick.Mark@glasgow.ac.uk 46 47 Frances S Mair MD 48 Norie Miller Professor of General Practice 		Sean.MacBride-Stewart@ggc.scot.nhs.uk
 42 Professor of Nephrology 43 Institute of Cardiovascular and Medical Sciences, University of Glasgow 44 Glasgow, G12 8TA, UK 45 Patrick.Mark@glasgow.ac.uk 46 47 Frances S Mair MD 48 Norie Miller Professor of General Practice 		
 43 Institute of Cardiovascular and Medical Sciences, University of Glasgow 44 Glasgow, G12 8TA, UK 45 Patrick.Mark@glasgow.ac.uk 46 47 Frances S Mair MD 48 Norie Miller Professor of General Practice 		
 44 Glasgow, G12 8TA, UK 45 Patrick.Mark@glasgow.ac.uk 46 47 Frances S Mair MD 48 Norie Miller Professor of General Practice 		
 45 <u>Patrick.Mark@glasgow.ac.uk</u> 46 47 Frances S Mair MD 48 Norie Miller Professor of General Practice 		
 46 47 Frances S Mair MD 48 Norie Miller Professor of General Practice 		
 47 Frances S Mair MD 48 Norie Miller Professor of General Practice 		<u>Patrick.wark@glasgow.ac.uk</u>
48 Norie Miller Professor of General Practice		Frances S Mair MD
	48 49	Institute of Health and Wellbeing, University of Glasgow

50 Glasgow G12 9LX, UK

It is made available under a CC-BY-NC-ND 4.0 International license .

1	Frances.mair@glasgow.ac.uk	
2		
3	Jill P Pell MD	
4	Henry Mechan Professor of F	Public Health
5	Institute of Health and Wellb	eing, University of Glasgow
6	Glasgow, G12 8RZ, UK	
7	Jill.pell@glasgow.ac.uk	
8		
9		
10		
11	*Address for correspondent	ce:
12	Professor Jill Pell	
13	Director of the Institute of He	ealth and Wellbeing
14	University of Glasgow	
15	1 Lilybank Gardens	
16	Glasgow G12 8RZ	
17	United Kingdom	
18	Jill.pell@glasgow.ac.uk	
19		
20		
21	Abstract word count	200
22	Main text word count	2,964
23	Tables	5
24	Supplementary Tables	2
25	Supplementary Figures	1
26	Number of references	34

It is made available under a CC-BY-NC-ND 4.0 International license .

1 Abstract

2 Many western countries used shielding (extended self-isolation) of people presumed to be at 3 high-risk from COVID-19 to protect them and reduce healthcare demand. To investigate the 4 effectiveness of this strategy, we linked family practitioner, prescribing, laboratory, hospital 5 and death records and compared COVID-19 outcomes among shielded and non-shielded 6 individuals in the West of Scotland. Of the 1.3 million population, 27,747 (2.03%) were 7 advised to shield, and 353,085 (26.85%) were classified a priori as moderate risk. COVID-19 8 testing was more common in the shielded (7.01%) and moderate risk (2.03%) groups, than 9 low risk (0.73%). Referent to low-risk, the shielded group had higher confirmed infections 10 (RR 8.45, 95% 7.44-9.59), case-fatality (RR 5.62, 95% CI 4.47-7.07) and population 11 mortality (RR 57.56, 95% 44.06-75.19). The moderate-risk had intermediate confirmed 12 infections (RR 4.11, 95% CI 3.82-4.42) and population mortality (RR 25.41, 95% CI 20.36-13 31.71) but, due to their higher prevalence, made the largest contribution to deaths (PAF 75.30%). Age ≥70 years accounted for 49.55% of deaths. In conclusion, shielding has not 14 15 been effective at preventing deaths in individuals at high risk. Also, to be effective as a 16 population strategy, shielding criteria would need to be widely expanded to include other 17 criteria, such as the elderly.

18

19 Keywords (Mesh terms):

- 20 Cohort studies; COVID-19; epidemiology; vulnerable populations
- 21

It is made available under a CC-BY-NC-ND 4.0 International license .

1 Introduction

2

Early in the COVID-19 pandemic, a major concern was that the demand on health services
would exceed capacity in terms of hospitalisations, intensive care unit (ICU) admissions, and
ventilation ¹. It was assumed that sub-groups of the population would have worse prognosis
and, therefore, contribute disproportionately to adverse outcomes and healthcare demands.
Asian countries generally relied on population-wide strategies ². Early, widespread 'test,
trace, isolate' strategies were made possible by higher testing capacity and greater

10 willingness to monitor and enforce compliance. In contrast, Europe and the USA adopted a

11 two-pronged approach; ² general population interventions, such as physical distancing and

12 hand hygiene, designed to reduce transmission in the population as a whole, supplemented by

13 shielding of those assumed to be at higher risk. Notably, Sweden, an outlier in not applying

14 lock-down, nonetheless mandated shielding³.

15

In the UK, a Vulnerable Patient List (Supplementary Table 1)⁶ was produced comprising two 16 17 categories labelled high risk, highest risk or clinically extremely vulnerable and moderate 18 risk, at risk or clinically vulnerable by various UK organisations. In this manuscript, they are 19 referred to as shielded and moderate risk respectively, with the remaining population labelled 20 low-risk. In the UK, the shielded group received individual letters strongly recommending 21 they self-isolate over a protracted period - not leaving their homes and avoiding non-essential 22 contact with household members - and were provided with support at home such as delivery 23 of food packages. The moderate risk category was simply advised to be vigilant in adhering 24 to general advice.

25

It is made available under a CC-BY-NC-ND 4.0 International license .

1	The category definitions were based largely on expert opinion informed by our understanding
2	of previous viruses and the need for better definitions has been highlighted ⁷ . Studies are
3	emerging of the risk factors associated with COVID-19 outcomes. Among two million UK
4	community-based app users self-reported heart disease, kidney disease, lung disease, diabetes
5	and obesity were associated with self-reported hospital admission and respiratory support for
6	COVID-19 ⁸ . Similarly, linkage of family practitioner records of 17 million people in
7	England reported a wide range of long-term conditions associated with in-hospital death from
8	COVID-19 including: respiratory, heart, liver and kidney disease, diabetes, cancers, stroke
9	and organ transplantation ⁹ . Unfortunately, the investigators did not have access to deaths in
10	the community. COVID-19 risk scores are being developed in an attempt to improve
11	identification of high risk individuals who could be advised to shield ¹⁰ but attempts to
12	investigate the potential contribution of a shielding strategy to population-level outcomes and
13	healthcare demands have so far been limited to mathematical modelling ^{11–19} .
14	
15	The aims of this study were to compare those classified, a priori, as high risk (and therefore
16	advised to shield) and those classified as moderate and low-risk, in terms of their individual
17	risk of COVID-19 infection and outcomes and the extent to which they accounted for
18	COVID-19 related outcomes at a population level.
19	
20	
21	Results
22	
23	Of the 1,315,071 people registered with family practitioners in NHS Greater Glasgow and
24	Clyde in the West of Scotland, 26,747 (2.03%) were on the shielding list and 353,085
25	(26.85%) were classified, a priori, as moderate-risk. Of the 26,747 shielded group, 18,147

medRxiv preprint doi: https://doi.org/10.1101/2020.09.17.20196436; this version posted November 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

1	(55.78%) had severe respiratory disease, 5,349 (16.44%) were on immunosuppressive
2	therapies, 2,491 (7.66%) had specific cancers, 1,245 (3.83%) had received organ transplants,
3	475 (1.78%) were on renal dialysis, and less than five were pregnant and had severe heart
4	disease. Of the 353,085 classified as moderate-risk, 160,215 (45.38%) had hypertension,
5	151,865 (43.01%) had chronic lung disease, 139,568 (39.53%) were ≥70 years of age, 64,358
6	(18.23%) had diabetes, 48,571 (13.81%) had heart disease, and 1,195 (0.34%) had a
7	weakened immune system.
8	
9	Shielded and moderate-risk categories
10	
11	Overall, 15,865 (1.21%) people were tested for COVID-19. The likelihood of being tested
12	increased with age, was higher in women and the moderate-risk category and highest in the
13	shielded group (Table 1). Overall, 3,348 (0.25%) people had confirmed COVID-19 infection.
14	The likelihood of laboratory-confirmed COVID-19 infection followed similar patterns as
15	testing. It increased with age, was higher in women, was highest in the shielded group and
16	lowest in the low-risk category (Table 2). After adjustment for sex and deprivation quintile,
17	the risk of laboratory-confirmed infection remained higher in the moderate-risk category and
18	highest in the shielded group (Table 3).
19	
20	Overall, 1,661 people were hospitalised for COVID-19. Within the general population,
21	hospitalisations increased with age but were comparable between men and women (Table 2).
22	Hospitalisations were more common in the moderate-risk category and most common in the
23	shielded group (Table 2), remaining so after adjustment for sex and deprivation (Table 3).

- 24 Overall, 122 people were admitted to ICU wards for COVID-19. ICU admissions were
- significantly more common among people aged 45-64 years of age than among older people

It is made available under a CC-BY-NC-ND 4.0 International license .

(Table 2). Compared with the low-risk category, the shielded group were 18 times more
likely to be hospitalised but only 4 times more likely to be admitted to ICU (Table 3).
Overall, 1,027 (0.08%) people died from COVID-19. Within the general population,
mortality increased with age but was similar in men and women (Table 2). Population
mortality was higher in the moderate-risk category and highest in the shielded group (Table
and remained so after adjustment for sex and deprivation (Table 3).

7

8 Among the sub-group with laboratory-confirmed (test-positive) COVID-19 infection, 1,661 9 (49.6%) were hospitalised. Hospitalisations increased with age but were comparable between 10 men and women (Table 4). The moderate-risk category was more likely to be hospitalised 11 and the shielded group most likely (Table 4), remaining so after adjustment for age and 12 deprivation (Table 5). Among those with laboratory-confirmed infection, ICU admissions 13 were more common in men and more common in people aged 45-64 years than those older 14 (Table 4). Low-risk cases were more likely to be admitted to ICU than the moderate-risk and 15 shielded groups (Tables 4 & 5). Among the sub-group with clinically-confirmed (test-16 positive or COVID-19 related death) COVID-19 infection, 1,027 (26.70%) died (Table 4). 17 Case-fatality increased by age and was higher in men than women. It was lowest in the low-18 risk category but not significantly different between the moderate-risk and shielded groups 19 (RR_{shielded/moderate} [95% CI] 1.12 [0.96-1.31], p=0.14) (Table 5).

20

The shielded group accounted for 7.62% of laboratory-confirmed COVID-19 infections, 12.70% of COVID-19 hospitalisations, 2.69% of ICU admissions and 13.22% of COVID-19 related deaths (Supplementary Table 2). The corresponding figures for the moderate-risk category were 42.06%, 53.28%, 22.96% and 75.30%. To prevent at least 80% of deaths, 28.8% of the population would have had to receive the current level of shielding including

It is made available under a CC-BY-NC-ND 4.0 International license .

1 those with five criteria classified as moderate- risk at the time of the study (Supplementary

2 Figure 1).

3

4 Individual risk criteria

5

6 Due to insufficient numbers, the individual risk criteria models could not be run for pregnant 7 women with severe heart disease or for COVID-19 related ICU admission in the shielded 8 category. All the remaining individual risk criteria were associated with higher likelihood of 9 being tested for COVID-19 (Table 1), laboratory-confirmed infection (Table 2), 10 hospitalisation, population mortality (Table 3) and case-fatality (Table 5) independent of sex 11 and deprivation. Among the moderate-risk category criteria, age \geq 70 years and weakened 12 immune system had risks of population mortality (Table 3) and case-fatality (Table 5) at least 13 as high as the overall shielded group. Apart from the 0.13% of people with relevant rare 14 diseases or inborn errors of metabolism and 1.78% on renal dialysis, the strongest 15 associations were observed for those aged \geq 70 years who were eight times as likely to have 16 confirmed infection (Table 3); seven times as likely to die following confirmed infection 17 (Table 5); and 74 times as likely to die overall (Table 3) compared with the low-risk 18 category. Being \geq 70 years of age accounted for 17.81% of confirmed COVID-19 infections, 19 22.19% of COVID-19 related hospitalisations, and 49.55% of COVID-19 related deaths 20 (Supplementary Table 2). Among those hospitalised for COVID-19, the likelihood of ICU 21 admission was significantly lower for all individual risk criteria in the moderate-risk 22 category, other than diabetes (Table 5). In particular, hospitalised patients \geq 70 years of age 23 were 14 times less likely to be admitted to ICU than low-risk hospitalised patients (Table 5).

24

25 **Discussion**

It is made available under a CC-BY-NC-ND 4.0 International license .

1

The 2.03% of people advised to shield were, nonetheless, eight times more likely to have confirmed infections than the low-risk category, five times more likely to die following confirmed infection and 49 times more likely to die from COVID-19 overall. Whilst selective testing might explain the first outcome, it does not explain higher overall mortality which suggests that the shielding strategy was not as effective as was hoped.

7

8 One quarter of the population were classified as moderate-risk and not advised to shield. 9 Nonetheless, they were four times more likely to have confirmed infections than the low-risk 10 category, five times more likely to die following confirmed infection and 25 times more 11 likely to die overall, suggesting that the shielding criteria should be expanded. In particular, 12 older age needs to be considered since the elderly are both at high individual risk and 13 contribute significantly to population burden due to their relatively high numbers.

14

In spite of people in the shielded and moderate-risk categories having poorer prognosis, they were less likely to be admitted to ICU following hospitalisation for COVID-19, especially patients ≥70 years. This finding reinforces the importance of protection in those with the worst prognosis.

19

Our finding that 26.85% of people satisfy moderate-risk criteria is consistent with limited existing evidence. A study linking English primary and secondary care records on 3.9 million people reported that 20% of population satisfied similar criteria²⁰. Similarly, analysis of the Global Burden of Diseases Study estimated that 22% of the global population are at increased risk of severe COVID-19 disease²¹. A USA study using data from the Behavioral Risk Factor Surveillance System reported that 45.4% of 444,649 adults had one or more of a longer list of

It is made available under a CC-BY-NC-ND 4.0 International license .

morbidities that may be associated with higher risk from COVID- 19^{22} . Another USA study 1 2 estimated that 14.2% of participants in the National Health Interview Survey had more than two-fold risk and 1.6% had more than 10-fold risk 23 . 3 4 5 The evidence on COVID-19 related complications among those classified as high risk, and 6 therefore advised to shield, has mainly come from case series and expert opinion. Case series 7 found higher COVID-19 related complications among organ transplant recipients^{24,25}, patients receiving chemotherapy, radiotherapy or immunotherapy for cancer^{26,27}, and patients 8 with haematological cancers²⁸. Systematic review suggested higher COVID-19 complication 9

10 risk among COPD patients, but the effect of COPD severity was not investigated²⁹. Patients

11 with cystic fibrosis and sickle cell disease were classified as high risk based on expert

12 opinion^{30,31}. While pregnant women with COVID-19 were found to have higher risk of poor

13 maternal and perinatal outcomes^{32,33}, outcomes were not investigated specifically for

14 pregnant women with heart disease. There was no evidence of worse COVID-19 related

15 complications among patients on immunosuppressants ³⁴. A large community study in

16 England found strong association between severe asthma (hazard ratio 1.25) and COVID-19

17 related mortality but did not investigate the risk of COVID-19 infection or hospitalisation⁹.

18

In common with previous studies, we demonstrated that age was a major individual-level risk factor for death. Additionally, we showed it is important at the population level with 49.55% of deaths attributable to age \geq 70 years. The higher mortality in the elderly was mediated in part by higher case-fatality but they also had a higher incidence of infection, possibly due to transmission within care homes. Lower ICU admissions following hospitalisation for COVID-19 may have contributed to their higher case-fatality. Previous studies have reported that men are at higher risk of COVID-19.⁷ Our study demonstrated they are less likely to be

medRxiv preprint doi: https://doi.org/10.1101/2020.09.17.20196436; this version posted November 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

tested for COVID-19, have confirmed infection, and be hospitalised. They have comparable
 overall mortality from COVID-19, due to their lower incidence, but their case-fatality is
 higher.

4

5 This study adds to the existing evidence of the possible effectiveness of a shielding strategy 6 which is currently limited to mathematical modelling of population effects based on assumptions ^{11–19}. Ours was a large-scale, unselected general population study. The data 7 8 cover a period when shielding was in place. Linkage of family practitioner, laboratory, 9 hospital and death data enabled us to examine a range of COVID-19 outcomes and study a 10 range of exposure variables including the overall risk categories and their individual criteria. 11 The datasets were linked using exact, rather than probabilistic, matching. We were able to 12 adjust for potential sociodemographic confounders. The exposure data were collected prior to 13 the outcomes occurring avoiding potential reverse causation and recall or recording bias. Our 14 analysis of potential risk factors was restricted to those used as criteria for shielding and 15 moderate-risk at the time of the study. The shielding and moderate-risk criteria were correct 16 at the time of extracting data but may be revised over time.

17

18 Our findings suggest that our attempts to shield those at highest risk have not been as 19 successful as hoped, with those advised to shield experiencing higher rates of infection and 20 death. Since this group was also less likely to be admitted to ICU, protecting them from 21 infection is essential. For shielding to be effective as a population level strategy, the current 22 criteria would need to be expanded since three-quarters of deaths were associated with 23 moderate-risk criteria for which shielding has not hitherto been recommended. In our study, 24 more than one-quarter of the general population would have needed to be effectively shielded 25 to prevent over 80% of deaths. Since this is unlikely to be acceptable at a time when

It is made available under a CC-BY-NC-ND 4.0 International license .

1	governments are under pressure to avoid further lock-downs, shielding is probably best
2	viewed as an individual-level intervention to be used alongside other population-wide
3	interventions such as physical distancing, face coverings and hand hygiene.
4	
5	
6	Methods
7	
8	We conducted a general population cohort study of all 1.3 million residents of NHS GGC in
9	the West of Scotland. The Community Health Index (CHI), a unique identifier attached to all
10	Scottish health records, enabled individual-level record linkage of nine databases:
11	Community Health Index (CHI) register, NHS GGC Shielding List, Egton Medical
12	Information Systems (EMIS) and Vision, Electronic Communication of Surveillance in
13	Scotland (ECOSS), Prescribing Information System (PIS), Strathclyde Electronic Renal
14	Patient Record (SERPR), Rapid Preliminary Inpatient Data (RAPID), and death certificates.
15	
16	The CHI register provided sociodemographic information (age, sex, area socioeconomic
17	deprivation). Deprivation was measured using the Scottish Index of Multiple Deprivation
18	(SIMD), derived from seven domains - income, education, health, employment, crime,
19	housing, and access to services - and categorised into general population quintiles. ECOSS
20	collects laboratory data on infectious diseases, including test date and result. Albasoft
21	software extract data from the family practitioner electronic health record systems EMIS and
22	Vision, and PIS collects data on medications prescribed by family practitioners. SERPR
23	records data on renal replacement therapy and transplantation. RAPID collects real-time data
24	on hospitalisation, including dates of admission and discharge, and type of ward, and the
25	Scottish Morbidity Record 01 (SMR01) subsequently records the relevant disease codes.

It is made available under a CC-BY-NC-ND 4.0 International license .

1	Death certificates provide the date and cause of all deaths, whether in-hospital or in the
2	community. Follow-up data were available until the end of May 2020, before the shielding
3	recommendation was lifted.
4	
5	Supplementary Table 1 lists the criteria for the shielded and medium risk categories applied
6	at the time of data extraction. All remaining patients are categorised as low-risk. The Scottish
7	list of high-risk individuals is compiled centrally, and regularly updated, using family
8	practitioner, hospital admission, disease registry and medication data. Family practitioners
9	check the completeness and accuracy of the list before letters, recommending shielding, are
10	sent to patients. The NHS GGC Shielding List we used contains the validated data including
11	the criterion satisfied. We ascertained moderate risk individuals using Albasoft extraction of
12	EMIS and Vision data, and PIS data.
13	
14	Separate models were conducted by overall risk category (low-risk, moderate-risk or
15	shielded) and by the individual criteria for the moderate-risk and shielded categories. The
16	four general population outcomes investigated were: confirmed COVID-19 infection;
17	COVID-19 related hospitalisation; COVID-19 related ICU admission; COVID-19 related
18	mortality. The three outcomes investigated among those with confirmed infection were:
19	COVID-19 related hospitalisation; COVID-19 related ICU admission; and COVID-19 related
20	case fatality.
21	
22	Laboratory-confirmed cases were defined as positive PCR test. Clinically-confirmed cases
23	were defined as either positive PCR test or death from COVID-19 without testing. COVID-
24	19 related deaths were defined as International Classification of Diseases 10 th revision (ICD-
25	10) code U07.1 or U07.2 recorded on the death certificate. COVID-related hospitalisation

It is made available under a CC-BY-NC-ND 4.0 International license .

1	was defined as an SMR01 hospitalisation record with an ICD code U07.1 or U07.2 or, for
2	more recent admissions, a RAPID hospitalisation record plus positive PCR test taken
3	between two weeks before and two days after hospitalisation. ICU admission during such
4	hospitalisations was assumed to be COVID-related.
5	
6	Sociodemographic characteristics were compared by risk category using chi-square tests.
7	Poisson regression models with robust standard errors were used to compare risk ratios (RR)
8	for the shielded and moderate-risk categories referent to the low-risk category. The models
9	were run univariately; then adjusted for sex and SIMD quintile as potential confounders. Age
10	was not included as a covariate because it was a moderate-risk criterion. The models were re-
11	run using the individual criteria for the shielded and moderate-risk categories as the exposure
12	variables, referent to the low-risk category.
13	
14	Population attributable fractions (PAFs) were calculated, from prevalence and adjusted RR,
15	to determine the proportion of each outcome that could be attributed to being shielded and
16	moderate-risk, as well as the proportion due to each individual criterion. The PAFs of
17	individual criteria were proportionally calibrated so that their sum equated to the overall PAF
18	of the relevant risk category. PAF confidence intervals were estimated using bootstrapping (x
19	1000).
20	
21	Ethical approvals
22	
23	The study was approved by the NHS GGC Primary Care Information Sharing Group and the
24	NHS GGC Local Privacy Advisory Committee (Reference GSH/20RM005) and was covered

It is made available under a CC-BY-NC-ND 4.0 International license .

- 1 by the generic Safe Haven Research Ethics Committee approval
- 2 (GSH20RM005_COVID_Community).
- 3
- 4

It is made available under a CC-BY-NC-ND 4.0 International license .

1 **References**

2	1.	Willan, J., King, A. J., Jeffery, K. & Bienz, N. Challenges for NHS hospitals during
3		covid-19 epidemic. <i>BMJ</i> 368 , (2020).
4	2.	ACAPS. #COVID19 A global joint response. (2020).
5	3.	Swedish Civil Contingencies Agency (MSB). National ban on visiting elderly homes.
6	0.	(2020).
7	4.	Radtke, T., Haile, S. R., Dressel, H. & Benden, C. Recommended shielding against
8	ч.	COVID-19 impacts physical activity levels in adults with cystic fibrosis. J. Cyst.
9		Fibros. (2020).
10	5.	Kemp, O., Horne, G. A. & Soutar, R. The psychological impact of COVID19 on a
10	5.	shielding high-risk cohort. Scott. Med. J. 0036933020951900 (2020).
12	6.	Public Health England. Guidance on shielding and protecting people who are clinically
12	0.	extremely vulnerable from COVID-19. (2020).
13 14	7.	Lipsitch, M., Swerdlow, D. L. & Finelli, L. Defining the Epidemiology of Covid-19 —
	1.	
15	0	Studies Needed. N. Engl. J. Med. 382 , 1194–1196 (2020).
16	8.	Lochlainn, M. N. <i>et al.</i> Key predictors of attending hospital with COVID19: An
17		association study from the COVID Symptom Tracker App in 2,618,948 individuals.
18	0	<i>medRxiv</i> 2020.04.25.20079251 (2020) doi:10.1101/2020.04.25.20079251.
19	9.	The OpenSAFELY et al. OpenSAFELY: factors associated with COVID-19-related
20		hospital death in the linked electronic health records of 17 million adult NHS patients.
21	10	<i>medRxiv</i> 2020.05.06.20092999 (2020) doi:10.1101/2020.05.06.20092999.
22	10.	Wynants, L. et al. Prediction models for diagnosis and prognosis of covid-19 infection:
23		systematic review and critical appraisal. BMJ 369, m1328 (2020).
24	11.	Vlas, S. J. de & Coffeng, L. E. A phased lift of control: a practical strategy to achieve
25		herd immunity against Covid-19 at the country level. medRxiv (2020)
26		doi:10.1101/2020.03.29.20046011.
27	12.	Keeling, M. J. et al. Predictions of COVID-19 dynamics in the UK: short-term
28		forecasting and analysis of potential exit strategies. medRxiv (2020)
29		doi:10.1101/2020.05.10.20083683.
30	13.	McKeigue, P. M. & Colhoun, H. M. Evaluation of 'stratify and shield' as a policy
31		option for ending the COVID-19 lockdown in the UK. medRxiv (2020)
32		doi:10.1101/2020.04.25.20079913.
33	14.	Bunnik, B. Van, Woolhouse, M. & van Bunnik, B. A. D. Segmentation and shielding
34		of the most vulnerable members of the population as elements of an exit strategy from
35		COVID-19 lockdown. medrxiv (2020) doi:10.1101/2020.05.04.20090597.
36	15.	Weitz, J. S. et al. Intervention Serology and Interaction Substitution: Modeling the
37		Role of 'Shield Immunity' in Reducing COVID-19 Epidemic Spread. medRxiv (2020)
38		doi:10.1101/2020.04.01.20049767.
39	16.	Neufeld, Z. & Khataee, H. Targeted adaptive isolation strategy for Covid-19
40		pandemic. medRxiv (2020) doi:10.1101/2020.03.23.20041897.
41	17.	Acemoglu, D., Chernozhukov, V., Werning, I. & Whinston, M. Optimal Targeted
42		Lockdowns in a Multi-Group SIR Model. (2020) doi:10.3386/w27102.
43	18.	Clark, A. et al. Global, regional, and national estimates of the population at increased
44		risk of severe COVID-19 due to underlying health conditions in 2020: a modelling
45		study. Lancet Glob. Heal. (2020) doi:10.1016/S2214-109X(20)30264-3.
46	19.	Davies, N. G. et al. Effects of non-pharmaceutical interventions on COVID-19 cases,
47		deaths, and demand for hospital services in the UK: a modelling study. Lancet Public
48		<i>Heal.</i> (2020) doi:10.1016/S2468-2667(20)30133-X.
49	20.	Banerjee, A. <i>et al.</i> Estimating excess 1-year mortality associated with the COVID-19

1		pandemic according to underlying conditions and age: a population-based cohort
2		study. Lancet (2020) doi:10.1016/s0140-6736(20)30854-0.
3	21.	Clark, A. et al. How many are at increased risk of severe COVID-19 disease? Rapid
4		global, regional and national estimates for 2020. medRxiv (2020)
5		doi:10.1101/2020.04.18.20064774.
6	22.	Adams, M. L., Katz, D. L. & Grandpre, J. Population based estimates of comorbidities
7		affecting risk for complications from COVID-19 in the US. medRxiv (2020)
8		doi:10.1101/2020.03.30.20043919.
9	23.	Jin, J., Agarwala, N., Kundu, P. & Chatterjee, N. Estimating the Size of High-risk
10		Populations for COVID-19 Mortality across 442 US Cities. (2020)
11		doi:10.1101/2020.05.27.20115170.
12	24.	Pereira, M. et al. COVID-19 in Solid Organ Transplant Recipients: Initial Report From
13		the US Epicenter. Am. J. Transplant (2020) doi:10.1111/AJT.15941.
14	25.	Fernández-Ruiz, M. et al. COVID-19 in Solid Organ Transplant Recipients: A Single-
15		Center Case Series From Spain. Am. J. Transplant (2020) doi:10.1111/AJT.15929.
16	26.	Zhang, L. et al. Clinical Characteristics of COVID-19-infected Cancer Patients: A
17		Retrospective Case Study in Three Hospitals Within Wuhan, China. Ann. Oncol. Off.
18		J. Eur. Soc. Med. Oncol. (2020) doi:10.1016/J.ANNONC.2020.03.296.
19	27.	Dai, M. et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multi-
20		center study during the COVID-19 outbreak. Cancer Discov. (2020)
21		doi:10.1158/2159-8290.CD-20-0422.
22	28.	He, W. et al. COVID-19 in persons with haematological cancers. Leukemia 1–9 (2020)
23		doi:10.1038/s41375-020-0836-7.
24	29.	Yang, J. et al. Prevalence of Comorbidities and Its Effects in Coronavirus Disease
25		2019 Patients: A Systematic Review and Meta-Analysis. Int. J. Infect. Dis. 94, (2020).
26	30.	Colombo, C. et al. Impact of COVID-19 on people with cystic fibrosis. Lancet Respir.
27		<i>Med.</i> 8 , e35–e36 (2020).
28	31.	Rodriguez-Morales, A. et al. Clinical, Laboratory and Imaging Features of COVID-19:
29		A Systematic Review and Meta-Analysis. Travel Med. Infect. Dis. (2020)
30		doi:10.1016/J.TMAID.2020.101623.
31	32.	Di Mascio, D. et al. Outcome of Coronavirus Spectrum Infections (SARS, MERS,
32		COVID 1 -19) During Pregnancy: A Systematic Review and Meta-Analysis. Am. J.
33		Obstet. Gynecol. MFM (2020) doi:10.1016/J.AJOGMF.2020.100107.
34	33.	Elshafeey, F. et al. A Systematic Scoping Review of COVID-19 During Pregnancy
35		and Childbirth. Int. J. Gynaecol. Obstet. (2020) doi:10.1002/IJGO.13182.
36	34.	Minotti, C., Tirelli, F., Barbieri, E., Giaquinto, C. & D, D. How Is Immunosuppressive
37		Status Affecting Children and Adults in SARS-CoV-2 Infection? A Systematic
38		Review. J. Infect. S0163-4453, (2020).
39		

It is made available under a CC-BY-NC-ND 4.0 International license .

1 Acknowledgements

2 We are extremely grateful to the following for their support and hard work in extracting and

3 linking the datasets and providing access to them: Charlie Mayor (Data Safe Haven

- 4 Manager), Alison Hamilton (Safe Haven Project Manager), Jonathan Todd (Head of
- 5 Information Management), Imran Sadat (Data Manager) and Neil Hillen (Data Analyst).
- 6

7 Contributors

8 FH and BJ contributed equally and are joint-first authors. BJ and JP conceptualised the study, 9 interpreted the data, and wrote the first draft of the manuscript. FH analysed the data and 10 wrote the first draft of the manuscript. All other authors interpreted the data and critically 11 revised the manuscript. All authors approved the final submitted version of the manuscript. 12 BJ, FH, and JP serve as the guarantor of the manuscript and accepts full responsibility for the 13 work and/or the conduct of the study, had access to the data, and controlled the decision to 14 publish. The corresponding author attests that all listed authors meet authorship criteria and 15 that no others meeting the criteria have been omitted.

16

17 **Conflicts of interest**

18 ICMJE All authors have completed the uniform disclosure form at 19 www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the 20 submitted work; no financial relationships with any organisations that might have an interest 21 in the submitted work in the previous three years; no other relationships or activities that 22 could appear to have influenced the submitted work.

23

24 Funding

25 No external funding sources.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 2 criteria
- 3
- 4

	COVI	D-19 testing status	
	Not tested	Tested	
	N=1,299,206	N=15,865	
	n (%)	n (%)	P value
Age group (years)			< 0.0001
0-24	355,238 (99.49)	1,822 (0.51)	
25-44	410,408 (99.22)	3,247 (0.78)	
45-64	340,268 (98.65)	4,660 (1.35)	
≥65	193,292 (96.92)	6,136 (3.08)	
Sex			< 0.0001
Male	654,041 (99.01)	6,569 (0.99)	
Female	645,165 (98.58)	9,296 (1.42)	
Deprivation quintile			< 0.0001
1 (most deprived)	461,672 (98.67)	6,211 (1.33)	
2	230,402 (98.75)	2,921 (1.25)	
3	194,702 (98.90)	2,175 (1.10)	
4	173,456 (98.93)	1,883 (1.07)	
5 (most affluent)	238,974 (98.89)	2,675 (1.11)	
Risk category			< 0.0001
Low	928,420 (99.27)	6,819 (0.73)	
Moderate	345,913 (97.97)	7,172 (2.03)	
Shielded	24,873 (92.99)	1,874 (7.01)	
Moderate risk criteria			
Chronic respiratory disease	149,325 (98.33)	2,540 (1.67)	< 0.0001
Heart disease	46,728 (96.21)	1,843 (3.79)	< 0.0001
Hypertension	156,286 (97.55)	3,929 (2.45)	< 0.0001
Diabetes	62,482 (97.09)	1,876 (2.91)	< 0.0001
Weakened immune system	1,140 (95.40)	55 (4.60)	< 0.0001
≥70 years of age	134,305 (96.23)	5,263 (3.77)	< 0.0001
Shielded criteria			
Severe respiratory disease	17,146 (94.48)	1,001 (5.52)	< 0.0001
Specific cancers	2,075 (83.30)	416 (16.70)	< 0.0001
Pregnant with severe heart disease	<5	0	-
Immunosuppressive therapy	5,028 (94.00)	321 (6.00)	< 0.0001
Solid organ transplant	1,149 (92.29)	96 (7.71)	< 0.0001
Rare diseases and inborn errors of metabolism	1,623 (91.95)	142 (8.05)	< 0.0001
Renal dialysis	305 (64.21)	170 (35.79)	< 0.0001

5 6

N number

¹ **Table 1.** COVID-19 testing status by sociodemographic characteristics, risk category and risk

	Confirmed	COVID-19 infecti	on	COVID-1	COVID-19 hospitalisation			9 ICU admissio	n	COVII	0-19 mortality	
	Negative test/ Not tested	Positive test	P-value	Not admitted	Admitted	P-value	Not admitted	Admitted	P-value	Alive	Dead	P-value
	N=1,311,723	N=3,348		N=1,313,410	N=1,661		N=1,314,949	N=122		N=1,314,044	N=1,027	
	n (%)	n (%)		n (%)	n (%)		n (%)	n (%)		n (%)	n (%)	=
Age group (years)			< 0.0001			< 0.0001			0.0005			<0.0000
0-24	356,944 (99.97)	116 (0.03)		357,041 (99.99)	19 (0.01)		357,060 (100.00)	0		357,060 (100.00)	0 (0.00)	Э
25-44	413,123 (99.87)	532 (0.13)		413,532 (99.97)	123 (0.03)		413,643 (100.00)	12 (0.00)		413,647 (100.00)	8 (0.00)	ad
45-64	343,856 (99.69)	1,072 (0.31)		344,409 (99.85)	519 (0.15)		344,846 (99.98)	82 (0.02)		344,838 (99.97)	90 (0.03)	made availaધe uter a 0. vter a
≥65	197,800 (99.18)	1,628 (0.82)		198,428 (99.50)	1,000 (0.50)		199,400 (99.99)	28 (0.01)		198,499 (99.53)	929 (0.47)	SAE
Sex												aila
Male	659,203 (99.79)	1,407 (0.21)	< 0.0001	659,781 (99.87)	829 (0.13)	0.81	660,525 (99.99)	85 (0.01)	< 0.0001	660,092 (99.92)	518 (0.08)	0.92
Female	652,250 (99.70)	1,941 (0.30)		659,369 (99.87)	832 (0.13)		660,908 (99.99)	37 (0.01)		653,952 (99.92)	509 (0.08)	e C
Deprivation quintile			0.0002			< 0.0001			0.18			<0.0
1 (most deprived)	466,582 (99.72)	1,301 (0.28)		467,146 (99.84)	737 (0.16)		467,832 (99.99)	51 (0.01)		467,442 (99.91)	441 (0.09)	er
2	232,710 (99.74)	613 (0.26)		233,041 (99.88)	282 (0.12)		233,302 (99.99)	21 (0.01)		233,181 (99.94)	142 (0.06)	b
3	196,416 (99.77)	461 (0.23)		196,651 (99.89)	226 (0.11)		196,854 (99.99)	23 (0.01)		196,724 (99.92)	153 (0.08)	8
4	174,939 (99.77)	400 (0.23)		175,143 (99.89)	196 (0.11)		175,329 (99.99)	10 (0.01)		175,209 (99.93)	130 (0.07)	ц.
5 (most affluent)	241,076 (99.76)	573 (0.24)		241,429 (99.91)	220 (0.09)		241,632 (99.99)	17 (0.01)		241,488 (99.93)	161 (0.07)	u酸01 <0.艘r a CC-BY-N的1 <0.爬-ND 、
Risk category	,,	,	< 0.0001	, ,	(,	< 0.0001	,,		< 0.0001	,,	(,	<0.0001
Low	934,049 (99.87)	1,190 (0.13)		93,4839 (99.96)	400 (0.04)		935,174 (99.99)	65 (0.01)		935,155 (99.99)	84 (0.01)	
Moderate	351,226 (99.47)	1,859 (0.53)		35,2054 (99.71)	1,031 (0.29)		353,033 (99.99)	52 (0.01)		352,282 (99.77)	803 (0.23)	Ð
Shielded	26,448 (98.88)	299 (1.12)		26,517 (99.14)	230 (0.86)		26,742 (99.98)	5 (0.02)		26,607 (99.48)	140 (0.52)	<0.0001 <0.0001
Moderate risk criteria	20,110 (20.00)	2)) (1.12)		20,517 (55.11)	250 (0.00)		20,712 ()).90)	5 (0.02)		20,007 (55.10)	110 (0.52)	0 4.0 li
Chronic respiratory disease	151,414 (99.70)	451 (0.30)	0.0005	151,618 (99.84)	247 (0.16)	< 0.0001	151,853 (99.99)	12 (0.01)	0.65	151,812 (99.97)	53 (0.03)	
Heart disease	48,176 (99.19)	395 (0.81)	< 0.0001	48,325 (99.49)	246 (0.51)	< 0.0001	48,564 (99.99)	7 (0.01)	0.34	48,456 (99.76)	115 (0.24)	
Hypertension	159,267 (99.41)	948 (0.59)	<0.0001	159,670 (99.66)	545 (0.34)	< 0.0001	160,189 (99.98)	26 (0.02)	0.003	159,991 (99.86)	224 (0.14)	<0 0001
Diabetes	63,903 (99.29)	455 (0.71)	< 0.0001	64,063 (99.54)	295 (0.46)	< 0.0001	64,335 (99.96)	23 (0.04)	< 0.0001	64,263 (99.85)	95 (0.15)	<0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Weakened immune system	1,183 (99.00)	12 (1.00)	< 0.0001	1,185 (99.16)	10 (0.84)	< 0.0001	1,195 (100.00)	0 (0.00)	-	1,189 (99.50)	6 (0.50)	< 0.0001
\geq 70 years of age	138,115 (98.96)	1,453 (1.04)	< 0.0001	138,701 (99.38)	867 (0.62)	< 0.0001	139,560 (99.99)	8 (0.01)	0.19	138,690 (99.37)	878 (0.63)	<0.0001
Shielded group		, ()						/		-,,		sus
Severe respiratory disease	17,981 (99.09)	166 (0.91)	< 0.0001	18,012 (99.26)	135 (0.74)	< 0.0001	18,146 (99.99)	<5	-	18,059 (99.52)	88 (0.48)	<0.0001
Specific cancers	2,452 (98.43)	39 (1.57)	< 0.0001	2,462 (98.84)	29 (1.16)	< 0.0001	2,491 (100.00)	0	-	2,475 (99.36)	16 (0.64)	< 0.0001
Pregnant, severe heart disease	<5	0	-	<5	0	-	<5	0	-	<5	0(0.00)	-
Immunosuppressive therapy	5,285 (98.80)	64 (1.20)	< 0.0001	5,299 (99.07)	50 (0.93)	< 0.0001	5,346 (99.94)	<5	-	5,324 (99.53)	25 (0.47)	< 0.0001
Solid organ transplant	1,228 (98.63)	17 (1.37)	< 0.0001	1,230 (98.80)	15 (1.20)	< 0.0001	1,244 (99.92)	<5	-	1,238 (99.44)	7 (0.56)	< 0.0001
Rare diseases and IEM	1,729 (97.96)	36 (2.04)	< 0.0001	1,741 (98.64)	24 (1.36)	< 0.0001	1,764 (99.94)	<5	-	1,744 (98.81)	21 (1.19)	<0.0001
Renal dialysis	445 (93.68)	30 (6.32)	< 0.0001	457 (96.21)	18 (3.79)	< 0.0001	475 (100.00)	0 (0.00)	-	468 (98.53)	7 (1.47)	< 0.0001

Table 2. Crude, population-level COVID-19 outcomes by sociodemographic characteristics, risk category and risk criteria

N number; IEM inborn errors of metabolism

	Confirmed COVID-1	9 infection	COVID-19 hospita	lisation	COVID-19 ICU a	dmission	COVID-19 morta	ality
	RR (95% CI)	P-value	RR (95% CI)	P-value	RR (95% CI)	P-value	RR (95% CI)	P-value
Low	1 (Reference)		1 (Reference)		1 (Reference)		1 (Reference)	
Moderate								
Overall	4.11 (3.83-4.42)	< 0.0001	6.83 (6.09-7.67)	< 0.0001	2.15 (1.49-3.10)	< 0.0001	25.41 (20.36-31.71)	< 0.0001
Chronic respiratory disease	2.30 (2.07-2.56)	< 0.0001	3.76 (3.21-4.41)	< 0.0001	1.15 (0.62-2.14)	0.65	3.88 (2.77-5.44)	< 0.0001
Heart disease	6.53 (5.83-7.31)	< 0.0001	11.63 (9.93-13.63)	< 0.0001	1.92 (0.88-4.20)	0.1	26.00 (19.71-34.31)	< 0.0001
Hypertension	4.60 (4.22-5.01)	< 0.0001	8.01 (7.04-9.11)	< 0.0001	2.44 (1.55-3.85)	0.0001	15.68 (12.24-20.09)	< 0.0001
Diabetes	5.59 (5.02-6.23)	< 0.0001	10.49 (9.03-12.19)	< 0.0001	4.89 (3.03-7.89)	< 0.0001	16.23 (12.16-21.66)	< 0.0001
Weakened immune system	7.79 (4.43-13.72)	< 0.0001	19.62 (10.50-36.69)	< 0.0001	-	-	56.19 (24.85-127.02)	< 0.0001
≥70 years of age	8.08 (7.48-8.72)	< 0.0001	14.96 (13.29-16.85)	< 0.0001	0.90 (0.43-1.86)	0.77	72.98 (58.81-90.55)	< 0.0001
Shielded								
Overall	8.45 (7.44-9.59)	< 0.0001	19.35 (16.45-22.77)	< 0.0001	2.78 (1.12-6.91)	0.03	57.56 (44.06-75.19)	< 0.0001
Severe respiratory disease	6.79 (5.78-7.99)	< 0.0001	16.40 (13.48-19.95)	< 0.0001	0.82 (0.11-5.89)	0.84	52.85 (39.31-71.05)	< 0.0001
Specific cancers	12.13 (8.83-16.65)	< 0.0001	27.21 (18.69-39.63)	< 0.0001	-	-	71.72 (42.36-121.42)	< 0.0001
Immunosuppressive therapy	9.25 (7.21-11.88)	< 0.0001	21.85 (16.30-29.29)	< 0.0001	8.40 (2.64-26.72)	0.0003	52.23 (33.64-81.08)	< 0.0001
Solid organ transplant	10.90 (6.77-17.55)	< 0.0001	27.77 (16.61-46.44)	< 0.0001	10.84 (1.50-78.16)	0.02	62.03 (29.03-132.56)	< 0.0001
Rare diseases and IEM	15.91 (11.44-22.12)	< 0.0001	31.45 (20.86-47.42)	< 0.0001	8.18 (1.13-58.93)	0.04	132.29 (82.60-211.86)	< 0.0001
Renal dialysis	50.29 (35.06-72.12)	< 0.0001	84.41 (52.70-135.20)	< 0.0001	-	-	158.41 (74.11-338.62)	< 0.0001

Table 3. Associations* between risk categories and risk criteria and population-level COVID-19 outcomes

*adjusted for sex and deprivation quintile RR relative risk; CI confidence interval; IEM inborn errors of metabolism

S

It is made available under a CC-BY-NC-ND 4.0 International license

	COVID-19 hospitalisation N=3,348 [†]			COVID-19 ICU admission N=3,348 [†]			COVID-19 case-fatality N=3,846 [‡]		
	Not admitted N=1,687 n (%)	Admitted N=1,661 n (%)	P-value	Not admitted N=3,226 n (%)	Admitted N=122 n (%)	P-value	Alive N=2,819 n (%)	Dead N=1,027 n (%)	P-value
Age group (years)			< 0.0001			< 0.0001			< 0.0001
0-24	97 (83.62)	19 (16.38)		116 (100.00)	0		116 (100.00)	0 (0.00)	
25-44	410 (76.92)	123 (23.08)		520 (97.74)	12 (2.26)		526 (98.50)	8 (1.50)	
45-64	553 (51.59)	519 (48.41)		990 (92.35)	82 (7.65)		1,003 (91.77)	90 (8.23)	
≥65	630 (38.65)	1,000 (61.35)		1,600 (98.28)	28 (1.72)		1,174 (55.83)	929 (44.17)	
Sex	,	,,		,			, ,		< 0.0001
Male	579 (41.12)	829 (58.88)	< 0.0001	1,322 (93.96)	85 (6.04)	< 0.0001	1,105 (68.08)	518 (31.92)	
Female	1,108 (57.11)	832 (42.89)		1,904 (98.09)	37 (1.91)		1,717 (77.10)	509 (22.90)	
Deprivation Quintile	-,		< 0.0001	-,	- (0.29	-,,		0.0004
1 (most deprived)	566 (43.44)	737 (56.56)		1,250 (96.08)	51 (3.92)		1,046 (70.34)	441 (29.66)	
2	332 (54.07)	282 (45.93)		592 (96.57)	21 (3.43)		531 (78.90)	142 (21.10)	
3	235 (50.98)	226 (49.02)		438 (95.01)	23 (4.99)		394 (72.03)	153 (27.97)	
4	204 (51.00)	196 (49.00)		390 (97.50)	10 (2.50)		341 (72.40)	130 (27.60)	
5 (most affluent)	353 (61.61)	220 (38.39)		556 (97.03)	17 (2.97)		507 (75.90)	161 (24.10)	
Risk category	000 (01101)	220 (00.00)	< 0.0001	220 () (102)	17 (21)77)	0.0001	007 (1000)	101 (2	< 0.0001
Low	791 (66.41)	400 (33.59)	(0.0001	1125 (94.54)	65 (5.46)	0.0001	1130 (93.08)	84 (6.92)	<0.0001
Moderate	828 (44.54)	1031 (55.46)		1807 (97.20)	52 (2.80)		1485 (64.90)	803 (35.10)	
Shielded	71 (23.59)	230 (76.41)		294 (98.33)	52 (2.80)		204 (59.30)	140 (40.70)	
Moderate risk criteria	71 (23.39)	250 (70.41)		294 (98.33)	5(1.07)		204 (39.30)	140 (40.70)	
	205 (45.35)	247 (54.65)	0.02	439 (97.34)	12 (2.66)	0.29	420 (88.79)	53 (11.21)	< 0.0001
Chronic respiratory disease Heart disease	149 (37.72)	247 (54.03) 246 (62.28)	< 0.002	388 (98.23)	7 (1.77)	0.29	330 (74.16)	115 (25.84)	0.0001
Hypertension	404 (42.57)	545 (57.43)	< 0.0001	922 (97.26)	26 (2.74)	0.049	836 (78.87)	224 (21.13)	< 0.0001
Diabetes	161 (35.31)	295 (64.69)	<0.0001	432 (94.95)	23 (5.05)	0.10	398 (80.73)	95 (19.27)	< 0.0001
Weakened immune system	2 (16.67)	10 (83.33)	0.04	12 (100.00)	23 (3.03)	-	6 (50.00)	6 (50.00)	0.13
≥70 years of age	587 (40.37)	867 (59.63)	< 0.0001	1,445 (99.45)	8 (0.55)	< 0.0001	1,035 (54.10)	878 (45.90)	< 0.0001
Shielding criteria	567 (40.57)	007 (57.05)	<0.0001	1,445 (77.45)	8 (0.55)	<0.0001	1,055 (54.10)	070 (45.90)	<0.0001
Severe respiratory disease	33 (19.64)	135 (80.36)	< 0.0001	165 (99.40)	<5		111 (55.78)	88 (44.22)	< 0.0001
Specific cancers	10 (25.64)	29 (74.36)	0.003	39 (100.00)	0	-	27 (62.79)	16 (37.21)	0.16
Pregnant, severe heart disease	10 (23.04)	2) (14.50)	0.005	57 (100.00)	-	-	-	-	-
Immunosuppressive therapy	14 (21.88)	50 (78.12)	< 0.0001	61 (95.31)	<5	_	42 (62.69)	25 (37.31)	0.07
Solid organ transplant	2 (11.76)	15 (88.24)	0.003	16 (94.12)	<5	-	11 (61.11)	7 (38.89)	0.07
Rare diseases and IEM	12 (33.33)	24 (66.67)	0.06	35 (97.22)	<5	-	23 (52.27)	21 (47.73)	0.003
Renal dialysis	12 (33.33)	18 (60.00)	0.33	30 (100.00)	0		23 (76.67)	7 (23.33)	0.83

Table 4. Crude COVID-19 outcomes among	confirmed cases b	v sociodemographic	characteristics	risk category and risk criteria
Table 4. Clude CO VID-17 Outcomes among	g commune cases o	y socioacinographic	characteristics,	, fisk categoly and fisk cificita

[†]laboratory-confirmed (test-positive) COVID-19 cases [‡]clinically-confirmed (test-positive or COVID-19 on death certificate) COVID-19 cases N number; IEM inborn errors of metabolism

It is made available under a CC-BY-NC-ND 4.0 International license

	COVID-19 hospitalisation $N=3,348^{\dagger}$		COVID-19 ICU a N=3,348		COVID-19 case-fatality N=3,846 [‡]	
	RR (95% CI)	P-value	RR (95% CI)	P-value	RR (95% CI)	P-value
Low	1 (Reference)		1 (Reference)		1 (Reference)	
Moderate						
Overall	1.34 (1.23-1.46)	< 0.0001	0.40 (0.28-0.58)	< 0.0001	5.01 (4.14-6.06)	< 0.0001
Chronic respiratory disease	1.55 (1.38-1.75)	< 0.0001	0.46 (0.25-0.86)	0.02	1.61 (1.21-2.16)	0.001
Heart disease	1.59 (1.41-1.79)	< 0.0001	0.24 (0.11-0.53)	0.0004	3.55 (2.79-4.50)	< 0.0001
Hypertension	1.53 (1.39-1.69)	< 0.0001	0.44 (0.28-0.70)	0.0004	3.04 (2.45-3.76)	< 0.0001
Diabetes	1.69 (1.51-1.90)	< 0.0001	0.72 (0.45-1.17)	0.19	2.62 (2.05-3.36)	< 0.0001
Weakened immune system	2.41 (1.50-3.86)	0.0003	-	-	7.09 (3.52-14.28)	< 0.0001
≥70 years of age	1.36 (1.24-1.48)	< 0.0001	0.07 (0.04-0.15)	< 0.0001	6.53 (5.42-7.88)	< 0.0001
Shielded						
Overall	1.89 (1.67-2.13)	< 0.0001	0.23 (0.09-0.56)	0.001	5.62 (4.47-7.07)	< 0.0001
Severe respiratory disease	1.92 (1.66-2.23)	< 0.0001	-	-	6.16 (4.78-7.93)	< 0.0001
Specific cancers	1.88 (1.41-2.49)	< 0.0001	-	-	5.00 (3.18-7.87)	< 0.0001
Immunosuppressive therapy	2.15 (1.73-2.69)	< 0.0001	-	-	5.15 (3.53-7.51)	< 0.0001
Solid organ transplant	2.31 (1.57-3.41)	< 0.0001	-	-	5.20 (2.71-9.99)	< 0.0001
Rare diseases and IEM	1.49 (1.09-2.03)	0.01	-	-	6.59 (4.39-9.89)	< 0.0001
Renal dialysis	1.61 (1.13-2.30)	0.009	-	-	3.10 (1.61-5.96)	0.0007

Table 5. Associations* between risk categories and risk criteria and COVID-19 outcomes among confirmed cases

*adjusted for sex and deprivation quintile [†]laboratory-confirmed (test-positive) COVID-19 cases [‡]clinically-confirmed (test-positive or COVID-19 on death certificate) COVID-19 cases N number; RR relative risk; CI confidence interval; IEM inborn errors of metabolism

It is made available under a CC-BY-NC-ND 4.0 International license